TITLE

Methoden zur frühen entwicklungsbegleitenden Bewertung innovativer medizinischer Technologien

AUTHOR(S)
Bartelmes, Marc; Neumann, Ulrike; Lühmann, Dagmar; Schönermark, Matthias P.; Hagen, Anja
PUB. DATE
January 2009
SOURCE
GMS Health Technology Assessment;2009, Vol. 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Conventional Health Technology Assessment (HTA) is usually conducted at a point in time at which the development of the respective technology may no longer be influenced. By this time developers and/or purchasers may have misinvested resources. Thus the demand for Technology Assessment (TA) which incorporates appropriate methods during early development stages of a technology becomes apparent. Against this health political background, the present report describes methods for a development-accompanying assessment of innovative medical technologies. Furthermore, international research programmes set out to identify or apply such methods will be outlined. A systematic literature search as well as an extensive manual literature search are carried out in order to obtain literature and information. The greatest units of the identified methods consist of assessment concepts, decision support methods, modelling approaches and methods focusing on users and their knowledge. Additionally, several general-purpose concepts have been identified. The identified research programmes INNO-HTA and MATCH (Multidisciplinary-Assessment-of-Technology-Centre-for-Healthcare) are to be seen as pilot projects which so far have not been able to generate final results. MATCH focuses almost entirely on the incorporation of the user-perspective regarding the development of nonpharmaceutical technologies, whereas INNO-HTA is basically concerned with the identification and possible advancement of methods for the early, socially-oriented technology assessment. Most references offer only very vague descriptions of the respective method and the application of greatly differing methods seldom exceeds the character of a pilot implementation. A standardisation much less an institutionalisation of development-accompanying assessment cannot be recognized. It must be noted that there is no singular method with which development-accompanying assessment should be carried out. Instead, a technology and evaluation specific method selection seem to be necessary as medical innovations are diverse and none of the methods are exhaustive. …
ACCESSION #
49390340

 

Related Articles

  • NEW MEDICAL TECHNOLOGY AIDS ALASKANS. Stomierowski, Peg // Alaska Business Monthly;Apr2009, Vol. 25 Issue 4, p102 

    The article discusses the technological innovations in medical care in Alaska. It presents some of the developments of medical technology including the eICU, an electronic monitoring systems that allows nurses and other health personnel to oversee ill or injured patients from a nearby location....

  • Technology in the crosshairs. Berci, G. // Surgical Endoscopy;Nov2003, Vol. 17 Issue 11, p1691 

    Comments on the addition of a new technology section in the periodical "Surgical Endoscopy,". Objectives of the new section; Recognition of the increasing role played by new technology in surgical endoscopy.

  • Incidental Findings and Ancillary-Care Obligations. Richardson, Henry S. // Journal of Law, Medicine & Ethics;Summer2008, Vol. 36 Issue 2, p256 

    Recent work on incidental fndings, concentrating on the difcult problems posed by the ambiguous results often generated by high-tech medicine, has proceeded largely independently from recent work on medical researchers' ancillary-care obligations, the obligations that researchers have to deal...

  • Reporting guidelines for modelling studies. Bennett, Carol; Manuel, Douglas G. // BMC Medical Research Methodology;2012, Vol. 12 Issue 1, p168 

    Background: Modelling studies are used widely to help inform decisions about health care and policy and their use is increasing. However, in order for modelling to gain strength as a tool for health policy, it is critical that key model factors are transparent so that users of models can have a...

  • Indirekte Vergleiche von Therapieverfahren. Schöttker, Ben; Lühmann, Dagmar; Boulkhemair, Dalila; Raspe, Heiner // GMS Health Technology Assessment;2009, Vol. 5, p1 

    Health political background The comparison of the effectiveness of health technologies is not only laid down in German law (Social Code Book V, § 139 and § 35b) but also constitutes a central element of clinical guidelines and decision making in health care. Tools supporting decision...

  • Manual and automated methods for identifying potentially preventable readmissions: a comparison in a large healthcare system. Jackson, Ana H.; Fireman, Emily; Feigenbaum, Paul; Neuwirth, Estee; Kipnis, Patricia; Bellows, Jim // BMC Medical Informatics & Decision Making;2014, Vol. 14 Issue 1, p1 

    Background Identification of potentially preventable readmissions is typically accomplished through manual review or automated classification. Little is known about the concordance of these methods. Methods We manually reviewed 459 30-day, all-cause readmissions at 18 Kaiser Permanente Northern...

  • Nichtmedikamentöse Sekundärprävention der koronaren Herzkrankheit (KHK). Müller-Riemenschneider, Falk; Damm, Kathrin; Meinhard, Charlotte; Bockelbrink, Angelina; Vauth, Christoph; Willich, Stefan N.; Greiner, Wolfgang // GMS Health Technology Assessment;2009, Vol. 5, p1 

    Background Coronary heart disease (CHD) is a common and potentially fatal malady with a life time prevalence of over 20%. For Germany, the mortality attributable to chronic ischemic heart disease or acute myocardial infarction is estimated at 140,000 deaths per year. An association between...

  • INTRODUCTION TO TRANSPLANT-LESS STEM CELL THERAPY. Gangar, H. U. // International Journal of Pharmaceutical Sciences Review & Resear;Nov2010, Vol. 5 Issue 3, p132 

    Stem cells are found in all multi cellular organisms. They possess the ability to renew themselves and also to differentiate into an intermediate cell type, which in turn, differentiate into diverse range of specialized cell types. The two broad types of stem cells are: embryonic stem cells and...

  • Surrogatendpunkte als Parameter der Nutzenbewertung. Mangiapane, Sandra; Velasco^Garrido, Marcial // GMS Health Technology Assessment;2009, Vol. 5, p1 

    The different actors involved in health system decision-making and regulation have to deal with the question which are valid parameters to assess the health value of health technologies. So called surrogate endpoints represent in the best case preliminary steps in the casual chain leading to the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics